25 XP   0   0   10

Milestone Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Milestone Pharmaceuticals Inc together

PenkeI guess you are interested in Milestone Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Milestone Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Milestone Pharmaceuticals Inc

I send you an email if I find something interesting about Milestone Pharmaceuticals Inc.

Quick analysis of Milestone Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Milestone Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.32
Expected worth in 1 year
$-0.62
How sure are you?
19.0%

+ What do you gain per year?

Total Gains per Share
$-0.93
Return On Investment
-57.2%

For what price can you sell your share?

Current Price per Share
$1.63
Expected price per share
$1.33 - $2.38
How sure are you?
50%

1. Valuation of Milestone Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.63

Intrinsic Value Per Share

$-6.70 - $-7.71

Total Value Per Share

$-6.39 - $-7.40

2. Growth of Milestone Pharmaceuticals Inc (5 min.)




Is Milestone Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$16.7m$82.7m-$47.8m-137.0%

How much money is Milestone Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$14.7m-$6.5m-$8.2m-55.6%
Net Profit Margin-360.0%-104.3%--

How much money comes from the company's main activities?

3. Financial Health of Milestone Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#611 / 1016

Most Revenue
#594 / 1016

Most Profit
#628 / 1016

Most Efficient
#709 / 1016

What can you expect buying and holding a share of Milestone Pharmaceuticals Inc? (5 min.)

Welcome investor! Milestone Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Milestone Pharmaceuticals Inc.

What can you expect buying and holding a share of Milestone Pharmaceuticals Inc?

First you should know what it really means to hold a share of Milestone Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Milestone Pharmaceuticals Inc is $1.63. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Milestone Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Milestone Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.32. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Milestone Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.26-15.7%-0.28-17.2%-0.27-16.8%-0.25-15.4%-0.25-15.2%
Usd Book Value Change Per Share-0.22-13.5%-0.23-14.3%-0.22-13.3%0.074.2%0.020.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.22-13.5%-0.23-14.3%-0.22-13.3%0.074.2%0.020.9%
Usd Price Per Share1.67-2.89-6.43-7.11-6.78-
Price to Earnings Ratio-1.63--2.56--5.85--1.82--1.74-
Price-to-Total Gains Ratio-7.57--12.37--30.72--16.72--16.72-
Price to Book Ratio5.29-4.68-4.17-3.98-3.79-
Price-to-Total Gains Ratio-7.57--12.37--30.72--16.72--16.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.63
Number of shares613
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.230.07
Usd Total Gains Per Share-0.230.07
Gains per Quarter (613 shares)-142.9541.51
Gains per Year (613 shares)-571.79166.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-572-5820166156
20-1144-11540332322
30-1715-17260498488
40-2287-22980664654
50-2859-28700830820
60-3431-34420996986
70-4003-4014011621152
80-4574-4586013281318
90-5146-5158014941484
100-5718-5730016601650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.020.00.04.8%1.020.00.04.8%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%4.017.00.019.0%4.017.00.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%4.017.00.019.0%4.017.00.019.0%

Fundamentals of Milestone Pharmaceuticals Inc

About Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Fundamental data was last updated by Penke on 2024-04-11 14:40:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Milestone Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Milestone Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-360.0%+360.0%
TTM-360.0%YOY-104.3%-255.7%
TTM-360.0%5Y-103.0%-257.0%
5Y-103.0%10Y-98.1%-4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM-360.0%-210.4%-149.6%
YOY-104.3%-279.3%+175.0%
5Y-103.0%-436.8%+333.8%
10Y-98.1%-599.3%+501.2%
1.1.2. Return on Assets

Shows how efficient Milestone Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • -18.1% Return on Assets means that Milestone Pharmaceuticals Inc generated $-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Milestone Pharmaceuticals Inc:

  • The MRQ is -18.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.1%TTM-16.2%-1.9%
TTM-16.2%YOY-5.8%-10.4%
TTM-16.2%5Y-10.7%-5.5%
5Y-10.7%10Y-10.7%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.1%-13.6%-4.5%
TTM-16.2%-12.9%-3.3%
YOY-5.8%-11.9%+6.1%
5Y-10.7%-14.2%+3.5%
10Y-10.7%-16.2%+5.5%
1.1.3. Return on Equity

Shows how efficient Milestone Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • -81.2% Return on Equity means Milestone Pharmaceuticals Inc generated $-0.81 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Milestone Pharmaceuticals Inc:

  • The MRQ is -81.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -50.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-81.2%TTM-50.1%-31.0%
TTM-50.1%YOY-5.9%-44.2%
TTM-50.1%5Y-17.2%-33.0%
5Y-17.2%10Y-16.3%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-81.2%-17.0%-64.2%
TTM-50.1%-16.1%-34.0%
YOY-5.9%-15.4%+9.5%
5Y-17.2%-20.0%+2.8%
10Y-16.3%-21.1%+4.8%

1.2. Operating Efficiency of Milestone Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Milestone Pharmaceuticals Inc is operating .

  • Measures how much profit Milestone Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-388.0%+388.0%
TTM-388.0%YOY-348.9%-39.1%
TTM-388.0%5Y-157.5%-230.5%
5Y-157.5%10Y-150.0%-7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-388.0%-224.4%-163.6%
YOY-348.9%-288.4%-60.5%
5Y-157.5%-475.2%+317.7%
10Y-150.0%-624.7%+474.7%
1.2.2. Operating Ratio

Measures how efficient Milestone Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.130-4.130
TTM4.130YOY5.654-1.524
TTM4.1305Y2.108+2.022
5Y2.10810Y2.008+0.100
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM4.1303.247+0.883
YOY5.6543.766+1.888
5Y2.1085.675-3.567
10Y2.0087.857-5.849

1.3. Liquidity of Milestone Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Milestone Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.11 means the company has $10.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 10.107. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.018. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.107TTM12.018-1.911
TTM12.018YOY17.111-5.093
TTM12.0185Y18.028-6.010
5Y18.02810Y18.095-0.066
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.1073.930+6.177
TTM12.0184.251+7.767
YOY17.1115.436+11.675
5Y18.0286.045+11.983
10Y18.0956.363+11.732
1.3.2. Quick Ratio

Measures if Milestone Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 16.90 means the company can pay off $16.90 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 16.897. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.028. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ16.897TTM18.028-1.131
TTM18.028YOY21.884-3.855
TTM18.0285Y22.481-4.453
5Y22.48110Y22.322+0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.8973.629+13.268
TTM18.0284.065+13.963
YOY21.8845.397+16.487
5Y22.4815.993+16.488
10Y22.3226.277+16.045

1.4. Solvency of Milestone Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Milestone Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Milestone Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.78 means that Milestone Pharmaceuticals Inc assets are financed with 77.7% credit (debt) and the remaining percentage (100% - 77.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 0.777. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.637. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.777TTM0.637+0.140
TTM0.637YOY0.077+0.560
TTM0.6375Y0.264+0.373
5Y0.26410Y0.329-0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7770.332+0.445
TTM0.6370.334+0.303
YOY0.0770.268-0.191
5Y0.2640.366-0.102
10Y0.3290.390-0.061
1.4.2. Debt to Equity Ratio

Measures if Milestone Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 348.5% means that company has $3.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Milestone Pharmaceuticals Inc:

  • The MRQ is 3.485. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.001. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.485TTM2.001+1.485
TTM2.001YOY0.084+1.916
TTM2.0015Y0.448+1.553
5Y0.44810Y0.427+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4850.381+3.104
TTM2.0010.390+1.611
YOY0.0840.334-0.250
5Y0.4480.434+0.014
10Y0.4270.466-0.039

2. Market Valuation of Milestone Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Milestone Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Milestone Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.63 means the investor is paying $-1.63 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Milestone Pharmaceuticals Inc:

  • The EOD is -1.591. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.630. Based on the earnings, the company is expensive. -2
  • The TTM is -2.556. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.591MRQ-1.630+0.039
MRQ-1.630TTM-2.556+0.926
TTM-2.556YOY-5.845+3.289
TTM-2.5565Y-1.822-0.734
5Y-1.82210Y-1.736-0.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.591-2.315+0.724
MRQ-1.630-2.560+0.930
TTM-2.556-2.664+0.108
YOY-5.845-4.122-1.723
5Y-1.822-6.258+4.436
10Y-1.736-6.108+4.372
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Milestone Pharmaceuticals Inc:

  • The EOD is -2.341. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.399. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.278. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.341MRQ-2.399+0.057
MRQ-2.399TTM-3.278+0.879
TTM-3.278YOY-6.602+3.324
TTM-3.2785Y-4.483+1.205
5Y-4.48310Y-4.269-0.213
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.341-3.067+0.726
MRQ-2.399-3.251+0.852
TTM-3.278-3.545+0.267
YOY-6.602-5.595-1.007
5Y-4.483-8.315+3.832
10Y-4.269-8.708+4.439
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Milestone Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.29 means the investor is paying $5.29 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Milestone Pharmaceuticals Inc:

  • The EOD is 5.166. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.292. Based on the equity, the company is overpriced. -1
  • The TTM is 4.676. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.166MRQ5.292-0.127
MRQ5.292TTM4.676+0.616
TTM4.676YOY4.165+0.511
TTM4.6765Y3.981+0.695
5Y3.98110Y3.792+0.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.1661.905+3.261
MRQ5.2922.111+3.181
TTM4.6762.095+2.581
YOY4.1652.836+1.329
5Y3.9813.443+0.538
10Y3.7923.794-0.002
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Milestone Pharmaceuticals Inc.

3.1. Institutions holding Milestone Pharmaceuticals Inc

Institutions are holding 33.661% of the shares of Milestone Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc9.76840.0001327074949000917.6215
2023-12-31RTW INVESTMENTS, LLC9.72460.0849325610200
2023-12-31Goldman Sachs Group Inc8.08210.000427061341474105.7611
2023-09-30VR Adviser, LLC6.59680.7208220881200
2023-12-31Alta Fundamental Advisers LLC4.99141.2612167128949510042.0936
2023-12-31Lion Point Capital, LP4.92851.378916502071200000266.5441
2023-12-31Millennium Management LLC4.46340.00111494489-200802-11.8447
2023-12-31Bleichroeder LP3.96050.4922132608500
2023-12-31Morgan Stanley - Brokerage Accounts2.05890.0001689400-11216-1.6009
2023-12-31Ikarian Capital, LLC1.38230.072446282800
2023-12-31BML Capital Management LLC1.32110.559544235216985262.331
2023-12-31Boxer Capital LLC0.92290.025730900700
2023-09-30Citadel Advisors Llc0.88490.0002296307-173443-36.9224
2023-12-31Barclays PLC0.76210.0002255185-390305-60.4665
2023-12-31Dimensional Fund Advisors, Inc.0.2201073704-13135-15.1257
2023-12-31Ancora Advisors LLC0.14930.00250000500000
2023-12-31Northern Trust Corp0.0955031970319700
2023-12-31Clear Creek Investment Mgmt LLC0.09480.0084317503211.0213
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC0.08240.00122758800
2023-12-31State Street Corporation0.064502161100
Total 60.55454.609320275569+1795761+8.9%

3.2. Funds holding Milestone Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31LUNIS Biotech Growth Opp Fd I a0.05061.65312690000
2024-03-28SPDR® S&P International Small Cap ETF0.03560.00531892300
2024-02-29Fidelity Nasdaq Composite Index0.03310.00021757600
2024-02-29Dimensional Global Core Equity USD Acc0.0110.0002586900
2024-02-29Dimensional Global Small Coms USD Acc0.00940.0006501600
2024-02-29Dimensional World Equity GBP Acc0.00690.0002365000
2024-02-29Dimensional Global Sust Cor Eq USD Acc0.00510.0001270000
2024-02-29Dimensional World Allc 60/40 GBP Acc0.00490.0001260200
2023-12-31JNL/DFA US Small Cap A0.00310.0005166100
2024-02-29Dimensional International Core Eq Acc0.0030.0002160000
2024-02-29Dimensional US Sm Company EUR Acc0.00270.0008143300
2023-12-31Dimensional US Small Cap CIT Class S0.00220.00041146573100
2024-02-29DFA US Vector Equity I0.0015078500
2023-09-30Blackstone Alternative Multi-Strategy I0.00110.000160000
Total 0.17021.661890461+573+0.6%

3.3. Insider Transactions

Insiders are holding 0.628% of the shares of Milestone Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-12-05David BharuchaBUY70004.69
2022-12-01David BharuchaBUY30004.86
2022-10-21Debra K LiebertBUY40005.26
2022-10-19Robert James WillsBUY150004.93
2022-09-07Rtw Investments, LpBUY15573468.71
2022-05-31Paul F TruexBUY50005.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Milestone Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.221-0.233+6%-0.218-1%0.068-426%0.015-1569%
Book Value Per Share--0.3160.657-52%1.557-80%1.639-81%1.512-79%
Current Ratio--10.10712.018-16%17.111-41%18.028-44%18.095-44%
Debt To Asset Ratio--0.7770.637+22%0.077+909%0.264+194%0.329+136%
Debt To Equity Ratio--3.4852.001+74%0.084+4027%0.448+678%0.427+717%
Dividend Per Share----0%-0%-0%-0%
Eps---0.256-0.281+10%-0.275+7%-0.250-2%-0.247-3%
Free Cash Flow Per Share---0.174-0.216+24%-0.248+43%-0.220+27%-0.216+24%
Free Cash Flow To Equity Per Share---0.1860.006-3400%-0.234+26%-0.019-90%0.047-495%
Gross Profit Margin--1.3661.258+9%1.075+27%1.022+34%1.029+33%
Intrinsic Value_10Y_max---7.713--------
Intrinsic Value_10Y_min---6.703--------
Intrinsic Value_1Y_max---0.821--------
Intrinsic Value_1Y_min---0.806--------
Intrinsic Value_3Y_max---2.429--------
Intrinsic Value_3Y_min---2.320--------
Intrinsic Value_5Y_max---3.994--------
Intrinsic Value_5Y_min---3.710--------
Market Cap86634174.000-2%88760166.000153602922.000-42%341753214.000-74%378107677.200-77%360102549.714-75%
Net Profit Margin----3.6000%-1.0430%-1.0300%-0.9810%
Operating Margin----3.8800%-3.4890%-1.5750%-1.5000%
Operating Ratio---4.130-100%5.654-100%2.108-100%2.008-100%
Pb Ratio5.166-2%5.2924.676+13%4.165+27%3.981+33%3.792+40%
Pe Ratio-1.591+2%-1.630-2.556+57%-5.845+259%-1.822+12%-1.736+6%
Price Per Share1.630-2%1.6702.890-42%6.430-74%7.114-77%6.775-75%
Price To Free Cash Flow Ratio-2.341+2%-2.399-3.278+37%-6.602+175%-4.483+87%-4.269+78%
Price To Total Gains Ratio-7.384+2%-7.565-12.369+63%-30.717+306%-16.715+121%-16.715+121%
Quick Ratio--16.89718.028-6%21.884-23%22.481-25%22.322-24%
Return On Assets---0.181-0.162-10%-0.058-68%-0.107-41%-0.107-41%
Return On Equity---0.812-0.501-38%-0.059-93%-0.172-79%-0.163-80%
Total Gains Per Share---0.221-0.233+6%-0.218-1%0.068-426%0.015-1569%
Usd Book Value--16771000.00034904500.000-52%82729500.000-80%87137000.000-81%80358571.429-79%
Usd Book Value Change Per Share---0.221-0.233+6%-0.218-1%0.068-426%0.015-1569%
Usd Book Value Per Share--0.3160.657-52%1.557-80%1.639-81%1.512-79%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.256-0.281+10%-0.275+7%-0.250-2%-0.247-3%
Usd Free Cash Flow---9251497.000-11490124.250+24%-13185250.000+43%-11704974.850+27%-11495737.952+24%
Usd Free Cash Flow Per Share---0.174-0.216+24%-0.248+43%-0.220+27%-0.216+24%
Usd Free Cash Flow To Equity Per Share---0.1860.006-3400%-0.234+26%-0.019-90%0.047-495%
Usd Market Cap86634174.000-2%88760166.000153602922.000-42%341753214.000-74%378107677.200-77%360102549.714-75%
Usd Price Per Share1.630-2%1.6702.890-42%6.430-74%7.114-77%6.775-75%
Usd Profit---13611000.000-14783250.000+9%-6570250.000-52%-11673150.000-14%-11580000.000-15%
Usd Revenue---250000.000-100%1250000.000-100%2550000.000-100%2428571.429-100%
Usd Total Gains Per Share---0.221-0.233+6%-0.218-1%0.068-426%0.015-1569%
 EOD+3 -5MRQTTM+14 -18YOY+11 -215Y+7 -2510Y+7 -25

4.2. Fundamental Score

Let's check the fundamental score of Milestone Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.591
Price to Book Ratio (EOD)Between0-15.166
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than116.897
Current Ratio (MRQ)Greater than110.107
Debt to Asset Ratio (MRQ)Less than10.777
Debt to Equity Ratio (MRQ)Less than13.485
Return on Equity (MRQ)Greater than0.15-0.812
Return on Assets (MRQ)Greater than0.05-0.181
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Milestone Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.422
Ma 20Greater thanMa 501.743
Ma 50Greater thanMa 1001.659
Ma 100Greater thanMa 2001.915
OpenGreater thanClose1.750
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets75,226
Total Liabilities58,455
Total Stockholder Equity16,771
 As reported
Total Liabilities 58,455
Total Stockholder Equity+ 16,771
Total Assets = 75,226

Assets

Total Assets75,226
Total Current Assets73,032
Long-term Assets2,194
Total Current Assets
Cash And Cash Equivalents 13,760
Short-term Investments 52,243
Net Receivables 3,851
Other Current Assets 3,178
Total Current Assets  (as reported)73,032
Total Current Assets  (calculated)73,032
+/-0
Long-term Assets
Property Plant Equipment 2,194
Long-term Assets  (as reported)2,194
Long-term Assets  (calculated)2,194
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,226
Long-term Liabilities51,229
Total Stockholder Equity16,771
Total Current Liabilities
Short-term Debt 546
Accounts payable 3,981
Other Current Liabilities 2,699
Total Current Liabilities  (as reported)7,226
Total Current Liabilities  (calculated)7,226
+/-0
Long-term Liabilities
Long term Debt 49,772
Capital Lease Obligations Min Short Term Debt1,457
Long-term Liabilities  (as reported)51,229
Long-term Liabilities  (calculated)51,229
+/-0
Total Stockholder Equity
Common Stock260,504
Retained Earnings -326,026
Accumulated Other Comprehensive Income 48,459
Other Stockholders Equity 33,834
Total Stockholder Equity (as reported)16,771
Total Stockholder Equity (calculated)16,771
+/-0
Other
Capital Stock260,504
Cash and Short Term Investments 66,003
Common Stock Shares Outstanding 33,483
Liabilities and Stockholders Equity 75,226
Net Debt 38,015
Net Invested Capital 66,543
Net Working Capital 65,806
Property Plant and Equipment Gross 2,385
Short Long Term Debt Total 51,775



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
88,081
77,588
151,837
141,892
123,428
105,156
93,139
108,797
149,974
138,443
145,495
133,776
119,849
105,799
91,299
85,769
74,483
111,080
97,019
87,116
75,226
75,22687,11697,019111,08074,48385,76991,299105,799119,849133,776145,495138,443149,974108,79793,139105,156123,428141,892151,83777,58888,081000
   > Total Current Assets 
0
0
0
88,051
77,279
151,551
140,971
122,499
104,324
92,406
107,419
148,686
137,244
144,386
132,758
118,923
104,966
90,502
82,921
71,803
108,508
94,566
84,797
73,032
73,03284,79794,566108,50871,80382,92190,502104,966118,923132,758144,386137,244148,686107,41992,406104,324122,499140,971151,55177,27988,051000
       Cash And Cash Equivalents 
0
0
0
85,947
71,239
110,824
106,501
119,818
101,816
53,426
46,910
72,310
71,859
97,794
111,426
114,141
92,241
63,237
37,286
7,636
73,953
32,591
9,879
13,760
13,7609,87932,59173,9537,63637,28663,23792,241114,141111,42697,79471,85972,31046,91053,426101,816119,818106,501110,82471,23985,947000
       Short-term Investments 
0
0
0
29
29
35,000
30,000
0
0
32,000
56,000
70,000
58,000
38,000
15,000
0
8,000
23,000
39,947
56,949
27,000
55,000
65,867
52,243
52,24365,86755,00027,00056,94939,94723,0008,000015,00038,00058,00070,00056,00032,0000030,00035,0002929000
       Net Receivables 
0
0
0
677
529
695
953
836
943
848
1,005
948
1,093
1,145
364
483
657
800
630
1,213
2,108
1,575
2,090
3,851
3,8512,0901,5752,1081,2136308006574833641,1451,0939481,005848943836953695529677000
       Other Current Assets 
0
0
0
1,398
5,482
5,032
3,517
1,845
1,565
6,132
3,504
5,428
6,292
7,447
5,968
4,299
4,068
3,465
5,058
6,336
6,861
5,883
7,530
3,178
3,1787,5305,8836,8616,3365,0583,4654,0684,2995,9687,4476,2925,4283,5046,1321,5651,8453,5175,0325,4821,398000
   > Long-term Assets 
0
0
0
30
309
286
921
929
832
733
1,378
1,288
1,199
1,109
1,018
926
833
797
2,848
2,680
2,572
2,453
2,319
2,194
2,1942,3192,4532,5722,6802,8487978339261,0181,1091,1991,2881,37873383292992128630930000
       Property Plant Equipment 
0
0
0
30
309
286
921
929
832
733
1,378
1,288
1,199
1,109
1,018
926
833
797
2,848
2,680
2,572
2,453
2,319
2,194
2,1942,3192,4532,5722,6802,8487978339261,0181,1091,1991,2881,37873383292992128630930000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
1,045
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,0450000000000
> Total Liabilities 
0
0
0
143,291
143,014
6,524
9,060
8,511
5,524
5,123
6,599
6,855
6,451
5,901
6,359
7,249
5,043
4,640
8,614
8,135
57,145
56,611
58,612
58,455
58,45558,61256,61157,1458,1358,6144,6405,0437,2496,3595,9016,4516,8556,5995,1235,5248,5119,0606,524143,014143,291000
   > Total Current Liabilities 
0
0
0
4,533
4,152
6,463
8,836
8,327
5,366
4,991
5,881
6,159
5,816
5,328
5,847
6,775
4,610
4,256
6,522
6,139
7,963
6,809
8,114
7,226
7,2268,1146,8097,9636,1396,5224,2564,6106,7755,8475,3285,8166,1595,8814,9915,3668,3278,8366,4634,1524,533000
       Short-term Debt 
0
0
0
0
168
175
358
330
196
157
234
245
252
259
254
224
198
169
487
495
507
522
530
546
5465305225074954871691982242542592522452341571963303581751680000
       Short Long Term Debt 
0
0
0
0
168
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001680000
       Accounts payable 
0
0
0
2,603
2,040
3,228
3,324
4,376
2,226
2,203
4,256
4,641
3,412
3,880
4,200
4,384
3,058
1,507
2,853
2,263
7,423
2,397
1,855
3,981
3,9811,8552,3977,4232,2632,8531,5073,0584,3844,2003,8803,4124,6414,2562,2032,2264,3763,3243,2282,0402,603000
       Other Current Liabilities 
0
0
0
1,930
2,112
3,235
5,512
3,951
3,140
2,788
1,391
1,273
2,152
1,189
1,393
2,167
1,354
2,580
3,182
3,381
33
6,287
7,584
2,699
2,6997,5846,287333,3813,1822,5801,3542,1671,3931,1892,1521,2731,3912,7883,1403,9515,5123,2352,1121,930000
   > Long-term Liabilities 
0
0
0
138,758
138,862
61
224
184
158
132
718
696
635
573
512
474
433
384
2,092
1,996
49,182
49,802
50,498
51,229
51,22950,49849,80249,1821,9962,09238443347451257363569671813215818422461138,862138,758000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,320
48,073
0
0
0048,07347,32000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
48,007
48,007
52,927
52,927
52,941
52,941
52,941
52,941
0
48,459
48,459
0
0
0048,45948,459052,94152,94152,94152,94152,92752,92748,00748,00700000000000
> Total Stockholder Equity
-33,119
0
0
-55,210
-65,426
145,313
132,832
114,917
99,632
88,016
102,198
143,119
131,992
139,594
127,417
112,600
100,756
86,659
77,155
66,348
53,935
40,408
28,504
16,771
16,77128,50440,40853,93566,34877,15586,659100,756112,600127,417139,594131,992143,119102,19888,01699,632114,917132,832145,313-65,426-55,21000-33,119
   Common Stock
0
0
0
2,039
2,090
226,211
226,211
226,245
226,378
226,676
226,758
251,682
251,716
251,716
251,766
251,901
251,990
252,236
254,937
273,900
260,126
260,169
260,502
260,504
260,504260,502260,169260,126273,900254,937252,236251,990251,901251,766251,716251,716251,682226,758226,676226,378226,245226,211226,2112,0902,039000
   Retained Earnings Total Equity00-297,334-281,2910-251,530-236,974-220,326-206,319-189,435-175,210-175,980-163,46600000000000
   Accumulated Other Comprehensive Income 
0
0
0
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
-1,634
34,352
48,459
48,459
48,459
48,459
48,45948,45948,45948,45934,352-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634-1,634000
   Capital Surplus 
0
0
0
0
2,840
3,116
3,466
3,805
4,730
0
0
8,530
9,883
11,795
13,793
15,711
17,785
20,090
22,441
0
26,641
29,114
0
0
0029,11426,641022,44120,09017,78515,71113,79311,7959,8838,530004,7303,8053,4663,1162,8400000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
1,032
1,206
1,482
1,832
2,220
3,096
4,161
30,240
54,903
57,890
64,722
66,720
68,652
70,726
73,031
75,382
24,437
26,641
29,114
31,958
33,834
33,83431,95829,11426,64124,43775,38273,03170,72668,65266,72064,72257,89054,90330,2404,1613,0962,2201,8321,4821,2061,032000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,000
Cost of Revenue-598
Gross Profit402402
 
Operating Income (+$)
Gross Profit402
Operating Expense-61,812
Operating Income-61,410-61,410
 
Operating Expense (+$)
Research Development31,272
Selling General Administrative15,932
Selling And Marketing Expenses15,114
Operating Expense61,81262,318
 
Net Interest Income (+$)
Interest Income3,503
Interest Expense-2,554
Other Finance Cost-857
Net Interest Income1,806
 
Pretax Income (+$)
Operating Income-61,410
Net Interest Income1,806
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-59,997-62,823
EBIT - interestExpense = -63,964
-59,997
-57,131
Interest Expense2,554
Earnings Before Interest and Taxes (EBIT)-61,410-57,443
Earnings Before Interest and Taxes (EBITDA)-60,812
 
After tax Income (+$)
Income Before Tax-59,997
Tax Provision-0
Net Income From Continuing Ops-59,251-59,997
Net Income-59,685
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses62,410
Total Other Income/Expenses Net1,413-1,806
 

Technical Analysis of Milestone Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Milestone Pharmaceuticals Inc. The general trend of Milestone Pharmaceuticals Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Milestone Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Milestone Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.98 < 2.19 < 2.38.

The bearish price targets are: 1.62 > 1.36 > 1.33.

Tweet this
Milestone Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Milestone Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Milestone Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Milestone Pharmaceuticals Inc. The current macd is 0.01666856.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Milestone Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Milestone Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Milestone Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Milestone Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartMilestone Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Milestone Pharmaceuticals Inc. The current adx is 25.39.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Milestone Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Milestone Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Milestone Pharmaceuticals Inc. The current sar is 1.98.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Milestone Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Milestone Pharmaceuticals Inc. The current rsi is 44.42. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Milestone Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartMilestone Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Milestone Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Milestone Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Milestone Pharmaceuticals Inc Daily Stochastic Oscillator ChartMilestone Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Milestone Pharmaceuticals Inc. The current cci is -109.23720955.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Milestone Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartMilestone Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Milestone Pharmaceuticals Inc. The current cmo is -23.21318173.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Milestone Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartMilestone Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Milestone Pharmaceuticals Inc. The current willr is -77.49434937.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Milestone Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Milestone Pharmaceuticals Inc Daily Williams %R ChartMilestone Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Milestone Pharmaceuticals Inc. The current atr is 0.13312513.

Milestone Pharmaceuticals Inc Daily Average True Range (ATR) ChartMilestone Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Milestone Pharmaceuticals Inc. The current obv is -22,671,179.

Milestone Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartMilestone Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Milestone Pharmaceuticals Inc. The current mfi is 60.39.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Milestone Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartMilestone Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Milestone Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Milestone Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Milestone Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.422
Ma 20Greater thanMa 501.743
Ma 50Greater thanMa 1001.659
Ma 100Greater thanMa 2001.915
OpenGreater thanClose1.750
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Milestone Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Milestone Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Milestone Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Milestone Pharmaceuticals Inc

I send you an email if I find something interesting about Milestone Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Milestone Pharmaceuticals Inc.

Receive notifications about Milestone Pharmaceuticals Inc in your mailbox!